This indicates that, although activating EGFR mutations are tumor specific, the MCF10A cell line is sensitive to pathogenic EGFR variants spanning cancer types, thereby offering new opportunities to interrogate multiple aspects of EGFR and its role in signaling and cancer. This evidence concerns the gene EGFR and cancer.